)

Innovent Biologics (1801) investor relations material
Innovent Biologics H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
Achieved total revenue of RMB5,953.1 million for 2025H1, up 50.6% year-over-year, driven by robust oncology and general biomedicine sales, and increased license income.
Net profit reached RMB834.3 million, a turnaround from a loss of RMB392.6 million in the prior year, with Non-IFRS net profit at RMB1,213.2 million and EBITDA at RMB1,412.8 million, reflecting improved operational efficiency.
Five new products launched, expanding the portfolio to 16 marketed products, sustaining oncology leadership and driving growth in general biomedicine.
Strategic collaborations, including a global license agreement with Roche for IBI3009, and global R&D expansion underpin international growth ambitions.
Cash reserves exceeded USD2.0 billion as of July 31, 2025, providing a strong financial base for future growth.
Financial highlights
Revenue: RMB5,953.1 million (+50.6% YoY); product revenue: RMB5,233.8 million (+37.3% YoY); license fee income: RMB665.6 million (up from RMB115.9 million YoY).
Gross profit: RMB5,119.6 million (+56.3% YoY); gross margin increased to 86.8% (Non-IFRS: 86.8%).
SG&A expenses ratio decreased by 7.9pp to 44.2%, and selling and marketing expenses were RMB2,375.1 million (39.9% of revenue).
Net profit: RMB834.3 million (vs. loss of RMB392.6 million YoY); Non-IFRS net profit: RMB1,213.2 million; Non-IFRS EBITDA: RMB1,412.8 million.
Cash and cash equivalents stood at over RMB11bn (USD1.5bn) as of June 30, 2025, and USD2bn as of July 31, 2025.
Outlook and guidance
2025 is positioned as a pivotal year, with continued revenue growth expected from oncology and new launches in general biomedicine.
Anticipates approvals for IBI112 and IBI310 by end of 2025, and further product launches and expanded indications.
Advancing global registrational studies for IBI363 and IBI343, with new PoC studies and Ph1 data accumulation planned.
Ongoing global expansion with late-stage clinical trials and regulatory submissions in multiple regions.
Three-year plan targets 20 commercial products and RMB20bn product revenue by 2027.
Next Innovent Biologics earnings date

Next Innovent Biologics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage